{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Cue Biopharma, Inc."},"Symbol":{"label":"Symbol","value":"CUE"},"Address":{"label":"Address","value":"21 ERIE STREET, CAMBRIDGE, Massachusetts, 02139, United States"},"Phone":{"label":"Phone","value":"+1 617 949-2680"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401."},"CompanyUrl":{"label":"Company Url","value":"https://www.cuebiopharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Daniel R. Passeri","title":"Chief Executive Officer & Director"},{"name":"Matteo Levisetti","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}